Alnylam Pharma (ALNY) Misses Q4 EPS by 11c
Tweet
Share
E-mailGet Alerts ALNY Hot Sheet
Price: $255.15 -1.9%
Revenue Growth %: +15.3%
Financial Fact:
Research and development: 83.17M
Today's EPS Names:
SUNB, CULP, KFY, More
Revenue Growth %: +15.3%
Financial Fact:
Research and development: 83.17M
Today's EPS Names:
SUNB, CULP, KFY, More
Join SI Premium – FREE
Alnylam Pharma (NASDAQ: ALNY) reported Q4 EPS of ($1.07), $0.11 worse than the analyst estimate of ($0.96). Revenue for the quarter came in at $7.6 million versus the consensus estimate of $9.1 million.
For earnings history and earnings-related data on Alnylam Pharma (ALNY) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Meta stock jumps 5% premarket: Analysts bullish on new Muse AI agent
- J.Jill (JILL) Tops Q2 EPS by 67c, Beats on Revenue; Offers Guidance
- Paychex (PAYX) PT Raised to $130 at Stifel
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
